Margaret A Fischl

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10381474/publications.pdf

Version: 2024-02-01

172457 254184 14,101 44 29 43 citations h-index g-index papers 45 45 45 5555 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex. New England Journal of Medicine, 1987, 317, 185-191.	27.0	2,601
2	A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less. New England Journal of Medicine, 1997, 337, 725-733.	27.0	2,532
3	Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection. New England Journal of Medicine, 1990, 322, 941-949.	27.0	1,312
4	Antiretroviral Therapy in Adults. JAMA - Journal of the American Medical Association, 2000, 283, 381.	7.4	951
5	Antiretroviral Treatment of Adult HIV Infection. JAMA - Journal of the American Medical Association, 2008, 300, 555.	7.4	846
6	Antiretroviral Therapy for HIV Infection in 1998. JAMA - Journal of the American Medical Association, 1998, 280, 78.	7.4	764
7	Treatment for Adult HIV Infection. JAMA - Journal of the American Medical Association, 2006, 296, 827.	7.4	755
8	Antiretroviral Treatment for Adult HIV Infection in 2002. JAMA - Journal of the American Medical Association, 2002, 288, 222.	7.4	632
9	The Safety and Efficacy of Zidovudine (AZT) in the Treatment of Subjects with Mildly Symptomatic Human Immunodeficiency Virus Type 1 (HIV) Infection. Annals of Internal Medicine, 1990, 112, 727.	3.9	570
10	Treatment for Adult HIV Infection. JAMA - Journal of the American Medical Association, 2004, 292, 251.	7.4	482
11	Comparison of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection. New England Journal of Medicine, 2003, 349, 2293-2303.	27.0	340
12	A Randomized Controlled Trial of a Reduced Daily Dose of Zidovudine in Patients with the Acquired Immunodeficiency Syndrome. New England Journal of Medicine, 1990, 323, 1009-1014.	27.0	332
13	Abacavir–Lamivudine versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy. New England Journal of Medicine, 2009, 361, 2230-2240.	27.0	289
14	Zidovudine treatment of the AIDS dementia complex: Results of a placebo-controlled trial. Annals of Neurology, 1993, 33, 343-349.	5.3	262
15	Prolonged Zidovudine Therapy in Patients With AIDS and Advanced AIDS-Related Complex. JAMA - Journal of the American Medical Association, 1989, 262, 2405.	7.4	161
16	A Comparison of Immediate with Deferred Zidovudine Therapy for Asymptomatic HIV-Infected Adults with CD4 Cell Counts of 500 or More per Cubic Millimeter. New England Journal of Medicine, 1995, 333, 401-407.	27.0	121
17	Antiviral Activity of Singleâ€Dose PRO 140, a CCR5 Monoclonal Antibody, in HIVâ€Infected Adults. Journal of Infectious Diseases, 2008, 198, 1345-1352.	4.0	115
18	Combination and Monotherapy with Zidovudine and Zalcitabine in Patients with Advanced HIV Disease. Annals of Internal Medicine, 1995, 122, 24.	3.9	111

#	Article	IF	CITATIONS
19	Fosamprenavir or atazanavir once daily boosted with ritonavir 100mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Research and Therapy, 2008, 5, 5.	1.7	91
20	Zalcitabine Compared with Zidovudine in Patients with Advanced HIV-1 Infection Who Received Previous Zidovudine Therapy. Annals of Internal Medicine, 1993, 118, 762.	3.9	81
21	Population Pharmacokinetics of Nevirapine, Zidovudine, and Didanosine in Human Immunodeficiency Virus-Infected Patients. Antimicrobial Agents and Chemotherapy, 1999, 43, 121-128.	3.2	81
22	A Randomized Trial of 2 Different 4â€Drug Antiretroviral Regimens versus a 3â€Drug Regimen, in Advanced Human Immunodeficiency Virus Disease. Journal of Infectious Diseases, 2003, 188, 625-634.	4.0	77
23	A Randomized, Controlled, Double-Blind Study Comparing the Survival Benefit of Four Different Reverse Transcriptase Inhibitor Therapies (Three-Drug, Two-Drug, and Alternating Drug) for the Treatment of Advanced AIDS. Journal of Acquired Immune Deficiency Syndromes, 1998, 19, 339-349.	0.3	72
24	CD4 cell count as a surrogate endpoint in HIV clinical trials. Aids, 1998, 12, 1823-1832.	2.2	66
25	A Randomized Study of Serial Telephone Call Support to Increase Adherence and Thereby Improve Virologic Outcome in Persons Initiating Antiretroviral Therapy. Journal of Infectious Diseases, 2005, 192, 1398-1406.	4.0	62
26	Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. Aids, 1999, 13, 685-694.	2.2	44
27	Interferon-α2b With Protease Inhibitor-Based Antiretroviral Therapy in Patients With AIDS-Associated Kaposi Sarcoma. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 41, 149-153.	2.1	42
28	Racial Differences in Response to Antiretroviral Therapy for HIV Infection: An AIDS Clinical Trials Group (ACTG) Study Analysis. Clinical Infectious Diseases, 2013, 57, 1607-1617.	5.8	40
29	A Phase II Study of Recombinant Human Interferon-α2a and Zidovudine in Patients with AIDS-Related Kaposi's Sarcoma. Journal of Acquired Immune Deficiency Syndromes, 1996, 11, 379-384.	0.3	39
30	Antiretroviral therapy in combination with interferon for AIDS-related Kaposi's sarcoma. American Journal of Medicine, 1991, 90, S2-S7.	1.5	28
31	Open-Label Study of a Twice-Daily Indinavir 800-mg/Ritonavir 100-mg Regimen in Protease Inhibitor–Naive HIV-Infected Adults. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 31, 478-482.	2.1	27
32	AIDS clinical trials group: Phase I/II study of combination 2′,3′-dideoxycytidine and zidovudine in patients with acquired immunodeficiency syndrome (AIDS) and advanced AIDS-related complex. American Journal of Medicine, 1990, 88, S27-S30.	1.5	25
33	Intracellular Nucleoside Triphosphate Concentrations in HIV-Infected Patients on Dual Nucleoside Reverse Transcriptase Inhibitor Therapy. Antiviral Therapy, 2007, 12, 981-986.	1.0	24
34	Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen. Aids, 2007, 21, 325-333.	2.2	22
35	Long-Term Efficacy, Safety, and Tolerability of Indinavir-Based Therapy in Protease InhibitorNaive Adults with Advanced HIV Infection. Clinical Infectious Diseases, 2003, 37, 1119-1124.	5.8	17
36	A Randomized, Placebo-Controlled Trial of Abacavir Intensification in HIV-1–Infected Adults With Virologic Suppression on a Protease Inhibitor–Containing Regimen. HIV Clinical Trials, 2010, 11, 312-324.	2.0	16

#	Article	IF	CITATIONS
37	Safety and Antiviral Activity of Combination Therapy With Zidovudine, Zalcitabine, and Two Doses of Interferon-α2a in Patients With HIV. Journal of Acquired Immune Deficiency Syndromes, 1997, 16, 247-253.	0.3	16
38	A Randomized, Placebo-Controlled Trial of Abacavir Intensification in HIV-1–Infected Adults With Virologic Suppression on a Protease Inhibitor–Containing Regimen. HIV Clinical Trials, 2010, 11, 312-324.	2.0	14
39	Detection of Replication-Competent Human Immunodeficiency Virus Type 1 (HIV-1) in Cultures from Patients with Levels of HIV-1 RNA in Plasma Suppressed to Less Than 500 or 50 Copies Per Milliliter. Journal of Clinical Microbiology, 2002, 40, 2089-2094.	3.9	12
40	A Randomized Trial of Nelfinavir and Abacavir in Combination with Efavirenz and Adefovir Dipivoxil in HIV-1-Infected Persons with Virological Failure Receiving Indinavir. Antiviral Therapy, 2003, 8, 507-518.	1.0	10
41	Pharmacokinetics of Nelfinavir and Efavirenz in Antiretroviral-Nail`ve, Human Immunodeficiency Virus-Infected Subjects when Administered Alone or in Combination with Nucleoside Analog Reverse Transcriptase Inhibitors. Antimicrobial Agents and Chemotherapy, 2005, 49, 3558-3561.	3.2	9
42	Impact of Low Abundance HIV Variants on Response to Ritonavir-Boosted Atazanavir or Fosamprenavir Given Once Daily with Tenofovir/Emtricitabine in Antiretroviral-Naive HIV-Infected Patients. AIDS Research and Human Retroviruses, 2010, 26, 407-417.	1.1	9
43	Twice-Daily Trizivir versus Combivir-Abacavir in Antiretroviral-Experienced Adults with Human Immunodeficiency Virus-1 Infection: A Formulation-Switch Trial. Pharmacotherapy, 2003, 23, 1432-1440.	2.6	1
44	The Effect of Zidovudine on Patient Subgroups-Reply. JAMA - Journal of the American Medical Association, 1992, 267, 2473.	7.4	0